Navigation Links
Theravent, Inc. exceeds 4.5 million nights of sleep apnea and snoring treatment
Date:10/29/2013

SAN JOSE, Calif., Oct. 29, 2013 /PRNewswire/ -- Theravent, Inc., a medical device company providing noninvasive solutions for people with sleep disordered breathing, recently hit a milestone when their Provent® Sleep Apnea Therapy and Theravent™ Advanced Nightly Snore Therapy products exceeded 4.5 million nights of treatment, collectively. Both products feature Expiratory Positive Airway Pressure (EPAP) therapy to treat Obstructive Sleep Apnea (OSA) and snoring.

Clinically proven by leading sleep specialists to treat both snoring and OSA, EPAP therapy represents a breakthrough in the battle against sleep related breathing disorders. It features MicroValve technology, which attaches and covers the nostrils to create pressure during exhalation. EPAP keeps a person's airway open while they sleep and prevents sleep disordered breathing and snoring.

Since 2009, over four million nights of Provent have been prescribed to treat OSA patients, while more than 400,000 nights of Theravent have been used over the past year to stop snoring and achieve a quieter night's sleep.

"We're pleased to see these therapies helping people around the world by treating conditions that have been linked to serious health problems, such as high blood pressure, stroke and heart attack," said Theravent, Inc. CEO Matt Williams. "In addition, these treatments provide quieter nights for bed partners, who are often negatively affected by loss of sleep due to the sound of snoring."

Approximately 90 million Americans are suffering from either OSA or snoring. Provent, which is available only by prescription, has been validated in seven peer-reviewed clinical publications by renowned sleep experts providing consistent results in the treatment of all severities of OSA. This treatment is a simple, portable and less invasive alternative to CPAP machines for people with OSA.  Theravent, an over-the-counter product developed using similar technology as Provent, was rigorously tested in three clinical trials. The results, published in Sleep Diagnosis and Therapy, showed that it was effective in reducing and eliminating snoring.

"OSA and snoring are both global health issues in need of more effective treatment options," said Williams. "Provent and Theravent are easy to use, convenient and cost-effective for sufferers of such conditions, and are clinically proven to work."

Thousands of sleep physicians have recommended these therapies to treat patients with snoring or OSA. To learn more, visit www.theravent.com and www.proventtherapy.com, or call 1-888-SLP-WELL (1-888-757-9355).

About Theravent, Inc.
Theravent, Inc. is a privately-held medical device company dedicated to providing noninvasive medical solutions for people with sleep disordered breathing. Based on its innovative MicroValve technology and patented designs, Theravent, Inc. has developed a unique line of clinically-proven medical devices to address the continuum of sleep disorders from severe obstructive sleep apnea (OSA) to mild snoring. Theravent, Inc.'s devices work by creating expiratory positive airway pressure (EPAP). The company markets prescription-only Provent Sleep Apnea Therapy, a discreet, easy-to-use nasal device for the treatment of OSA, and Theravent Snore Therapy, an over-the-counter device for the treatment of primary snoring, in the US. Provent is also available in Australia, New Zealand, Canada, Hong Kong, Singapore and South Africa. For more information, please visit www.proventtherapy.com or www.theravent.com.


'/>"/>
SOURCE Theravent, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Specialty Pharmacy Association of America (SPAARx) - Enrollment Exceeds 1,000 Members in First Two Weeks since Launch
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Delcath Systems, Inc. Secures $20 Million Credit Facility
4. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
5. Arthrosurface Hits a $100 Million Milestone
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
8. Independa Closes Convertible Note Funding at $2.35 Million
9. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
10. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
11. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):